Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) completes recruitment for its US-based SARS-CoV2 clinical study, COVID-Cough
- The trial collects audio cough recordings and symptoms for 122 PCR-confirmed COVID-19 positive cases and 139 negative cases
- The clinical study is gathering data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone
- ResApp last traded at 6.2 cents on January 10
ResApp Health (RAP) has completed recruitment for its US-based SARS-CoV2 clinical study, COVID-Cough.
The US-based COVID-Cough Pilot clinical study aims to collect data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone using a gold-standard PCR pathology test.
It was successful in collecting audio cough recordings and self-reported symptoms for 122 polymerase chain reaction (PCR) confirmed COVID-19 positive cases and 139 negative cases.
CEO and Managing Director Dr Tony Keating said the company appreciates the support of participants who enrolled in the study and the work of its partners, Phosphorus and Covid Clinic, for assisting with recruitment.
“This US data, as well as data from our recently completed Indian clinical study and our datasets collected pre-COVID-19, provides us with a high-quality clinical dataset to build, train and validate algorithms for detection and monitoring of COVID-19,” said Dr Keating.
“As the fourth wave of COVID-19 spreads worldwide, our team is working hard to deliver algorithms for a much-needed, instant smartphone-based screening test and patient monitoring tools that could change the way the world lives with this virus.”
Shares in ResApp Health remain steady today at 6.2 cents each as of 12:04 pm AEDT.
